Abstract
HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have